Long-Term Outcomes in IgA Nephropathy

被引:138
作者
Pitcher, David [1 ,2 ]
Braddon, Fiona [1 ]
Hendry, Bruce [3 ]
Mercer, Alex [4 ]
Osmaston, Kate [1 ]
Saleem, Moin A. A. [5 ,6 ]
Steenkamp, Retha [1 ]
Wong, Katie [1 ,2 ]
Turner, A. Neil [7 ]
Wang, Kaijun [3 ]
Gale, Daniel P. P. [2 ]
Barratt, Jonathan [8 ,9 ,10 ]
机构
[1] UK Kidney Assoc, UK Renal Registry, Bristol, England
[2] UCL, Dept Renal Med, London, England
[3] Travere Therapeut Inc, San Diego, CA USA
[4] JAMCO Pharm Consulting, Stockholm, Sweden
[5] Univ Bristol, Bristol, England
[6] Bristol Royal Hosp Children, Bristol, England
[7] Univ Edinburgh, Edinburgh, Scotland
[8] Univ Leicester, Leicester, England
[9] Leicester Gen Hosp, Leicester, England
[10] Univ Leicester, Dept Cardiovasc Sci, Univ Rd, Leicester LE1 7RH, England
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2023年 / 18卷 / 06期
关键词
chronic kidney disease; chronic kidney failure; end-stage kidney disease (ESKD); end-stage renal disease (ESRD); IGA nephropathy; kidney disease; nephropathy; proteinuria; CHRONIC KIDNEY-DISEASE; URINE PROTEIN; ASSOCIATION; ALBUMINURIA; REMISSION; FAILURE; RISK;
D O I
10.2215/CJN.0000000000000135
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope, and lifetime risks for kidney failure. Methods The IgA nephropathy cohort (2299 adults and 140 children) of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed. Patients enrolled had a biopsy-proven diagnosis of IgA nephropathy plus proteinuria >0.5 g/d or eGFR <60 ml/min per 1.73 m(2). Incident and prevalent populations and a population representative of a typical phase 3 clinical trial cohort were studied. Analyses of kidney survival were conducted using Kaplan-Meier and Cox regression. eGFR slope was estimated using linear mixed models with random intercept and slope. Results The median (Q1, Q3) follow-up was 5.9 (3.0, 10.5) years; 50% of patients reached kidney failure or died in the study period. The median (95% confidence interval [CI]) kidney survival was 11.4 (10.5 to 12.5) years; the mean age at kidney failure/death was 48 years, and most patients progressed to kidney failure within 10-15 years. On the basis of eGFR and age at diagnosis, almost all patients were at risk of progression to kidney failure within their expected lifetime unless a rate of eGFR loss <= 1 ml/min per 1.73 m(2) per year was maintained. Time-averaged proteinuria was significantly associated with worse kidney survival and more rapid eGFR loss in incident, prevalent, and clinical trial populations. Thirty percent of patients with time-averaged proteinuria of 0.44 to <0.88 g/g and approximately 20% of patients with time-averaged proteinuria <0.44 g/g developed kidney failure within 10 years. In the clinical trial population, each 10% decrease in time-averaged proteinuria from baseline was associated with a hazard ratio (95% CI) for kidney failure/death of 0.89 (0.87 to 0.92). Conclusions Outcomes in this large IgA nephropathy cohort are generally poor with few patients expected to avoid kidney failure in their lifetime. Significantly, patients traditionally regarded as being low risk, with proteinuria <0.88 g/g (<100 mg/mmol), had high rates of kidney failure within 10 years.
引用
收藏
页码:727 / 738
页数:12
相关论文
共 21 条
  • [1] Association between albuminuria and proteinuria in the general population: the AusDiab Study
    Atkins, RC
    Briganti, EM
    Zimmet, PZ
    Chadban, SJ
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) : 2170 - 2174
  • [2] Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy
    Canney, Mark
    Barbour, Sean J.
    Zheng, Yuyan
    Coppo, Rosanna
    Zhang, Hong
    Liu, Zhi-Hong
    Matsuzaki, Keiichi
    Suzuki, Yusuke
    Katafuchi, Ritsuko
    Reich, Heather N.
    Cattran, Daniel
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (02): : 436 - 447
  • [3] A study of the relationship between albuminuria, proteinuria and urinary reagent strips
    Collier, Geraldine
    Greenan, Marie Clare
    Brady, Jennifer J.
    Murray, Barbara
    Cunningham, Sean K.
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2009, 46 : 247 - 249
  • [4] Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments
    Coppo, Rosanna
    Troyanov, Stephan
    Bellur, Shubha
    Cattran, Daniel
    Cook, H. Terence
    Feehally, John
    Roberts, Ian S. D.
    Morando, Laura
    Camilla, Roberta
    Tesar, Vladimir
    Lunberg, Sigrid
    Gesualdo, Loreto
    Emma, Francesco
    Rollino, Cristiana
    Amore, Alessandro
    Praga, Manuel
    Feriozzi, Sandro
    Segoloni, Giuseppe
    Pani, Antonello
    Cancarini, Giovanni
    Durlik, Magalena
    Moggia, Elisabetta
    Mazzucco, Gianna
    Giannakakis, Costantinos
    Honsova, Eva
    Sundelin, B. Brigitta
    Di Palma, Anna Maria
    Ferrario, Franco
    Gutierrez, Eduardo
    Asunis, Anna Maria
    Barratt, Jonathan
    Tardanico, Regina
    Perkowska-Ptasinska, Agnieszka
    [J]. KIDNEY INTERNATIONAL, 2014, 86 (04) : 828 - 836
  • [5] Global Health Observatory data repository, LIF EXP HLTH LIF EXP
  • [6] Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
    Hastings, M. Colleen
    Bursac, Zoran
    Julian, Bruce A.
    Baca, Emanuel Villa
    Featherston, Jennifer
    Woodford, Susan Y.
    Bailey, Lisa
    Wyatt, Robert J.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2018, 3 (01): : 99 - 104
  • [7] Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
    Inker, Lesley A.
    Heerspink, Hiddo J. L.
    Tighiouart, Hocine
    Chaudhari, Juhi
    Miao, Shiyuan
    Diva, Ulysses
    Mercer, Alex
    Appel, Gerald B.
    Donadio, James, V
    Floege, Jurgen
    Li, Philip K. T.
    Maes, Bart D.
    Locatelli, Francesco
    Praga, Manuel
    Schena, Francesco P.
    Levey, Andrew S.
    Greene, Tom
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (03) : 340 - +
  • [8] Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis
    Inker, Lesley A.
    Mondal, Hasi
    Greene, Tom
    Masaschi, Taylor
    Locatelli, Francesco
    Schena, Francesco P.
    Katafuchi, Ritsuko
    Appel, Gerald B.
    Maes, Bart D.
    Li, Philip K.
    Praga, Manuel
    Del Vecchio, Lucia
    Andrulli, Simeone
    Manno, Carlo
    Gutierrez, Eduardo
    Mercer, Alex
    Carroll, Kevin J.
    Schmid, Christopher H.
    Levey, Andrew S.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (03) : 392 - 401
  • [9] Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study
    Jarrick, Simon
    Lundberg, Sigrid
    Welander, Adina
    Carrero, Juan-Jesus
    Hoijer, Jonas
    Bottai, Matteo
    Ludvigsson, Jonas F.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (05): : 866 - 876
  • [10] Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population
    Le, WeiBo
    Liang, ShaoShan
    Hu, YangLin
    Deng, KangPing
    Bao, Hao
    Zeng, CaiHong
    Liu, ZhiHong
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (04) : 1479 - 1485